219 related articles for article (PubMed ID: 31390883)
1. ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors.
Kegulian NC; Ramms B; Horton S; Trenchevska O; Nedelkov D; Graham MJ; Lee RG; Esko JD; Yassine HN; Gordts PLSM
Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):2145-2156. PubMed ID: 31390883
[TBL] [Abstract][Full Text] [Related]
2. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.
Gordts PL; Nock R; Son NH; Ramms B; Lew I; Gonzales JC; Thacker BE; Basu D; Lee RG; Mullick AE; Graham MJ; Goldberg IJ; Crooke RM; Witztum JL; Esko JD
J Clin Invest; 2016 Aug; 126(8):2855-66. PubMed ID: 27400128
[TBL] [Abstract][Full Text] [Related]
3. Sialylated isoforms of apolipoprotein C-III and plasma lipids in subjects with coronary artery disease.
Olivieri O; Chiariello C; Martinelli N; Castagna A; Speziali G; Girelli D; Pizzolo F; Bassi A; Cecconi D; Robotti E; Manfredi M; Conte E; Marengo E
Clin Chem Lab Med; 2018 Aug; 56(9):1542-1550. PubMed ID: 29652662
[TBL] [Abstract][Full Text] [Related]
4. Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetes.
Koska J; Yassine H; Trenchevska O; Sinari S; Schwenke DC; Yen FT; Billheimer D; Nelson RW; Nedelkov D; Reaven PD
J Lipid Res; 2016 May; 57(5):894-905. PubMed ID: 26945091
[TBL] [Abstract][Full Text] [Related]
5. ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance.
Ramms B; Patel S; Nora C; Pessentheiner AR; Chang MW; Green CR; Golden GJ; Secrest P; Krauss RM; Metallo CM; Benner C; Alexander VJ; Witztum JL; Tsimikas S; Esko JD; Gordts PLSM
J Lipid Res; 2019 Aug; 60(8):1379-1395. PubMed ID: 31092690
[TBL] [Abstract][Full Text] [Related]
6. Hepatic remnant lipoprotein clearance by heparan sulfate proteoglycans and low-density lipoprotein receptors depend on dietary conditions in mice.
Foley EM; Gordts PLSM; Stanford KI; Gonzales JC; Lawrence R; Stoddard N; Esko JD
Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2065-74. PubMed ID: 23846497
[TBL] [Abstract][Full Text] [Related]
7. The Association of Human Apolipoprotein C-III Sialylation Proteoforms with Plasma Triglycerides.
Yassine HN; Trenchevska O; Ramrakhiani A; Parekh A; Koska J; Walker RW; Billheimer D; Reaven PD; Yen FT; Nelson RW; Goran MI; Nedelkov D
PLoS One; 2015; 10(12):e0144138. PubMed ID: 26633899
[TBL] [Abstract][Full Text] [Related]
8. Changes in low-density lipoprotein size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions.
Mendoza S; Trenchevska O; King SM; Nelson RW; Nedelkov D; Krauss RM; Yassine HN
J Clin Lipidol; 2017; 11(1):224-233.e2. PubMed ID: 28391889
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor.
Mann CJ; Troussard AA; Yen FT; Hannouche N; Najib J; Fruchart JC; Lotteau V; André P; Bihain BE
J Biol Chem; 1997 Dec; 272(50):31348-54. PubMed ID: 9395464
[TBL] [Abstract][Full Text] [Related]
10. Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women.
Wassef H; Bissonnette S; Dufour R; Davignon J; Faraj M
J Nutr; 2017 May; 147(5):754-762. PubMed ID: 28356429
[No Abstract] [Full Text] [Related]
11. Distribution of seven ApoC-III glycoforms in plasma, VLDL, IDL, LDL and HDL of healthy subjects.
Rodríguez M; Rehues P; Iranzo V; Mora J; Balsells C; Guardiola M; Ribalta J
J Proteomics; 2022 Jan; 251():104398. PubMed ID: 34688878
[TBL] [Abstract][Full Text] [Related]
12. A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.
Khetarpal SA; Zeng X; Millar JS; Vitali C; Somasundara AVH; Zanoni P; Landro JA; Barucci N; Zavadoski WJ; Sun Z; de Haard H; Toth IV; Peloso GM; Natarajan P; Cuchel M; Lund-Katz S; Phillips MC; Tall AR; Kathiresan S; DaSilva-Jardine P; Yates NA; Rader DJ
Nat Med; 2017 Sep; 23(9):1086-1094. PubMed ID: 28825717
[TBL] [Abstract][Full Text] [Related]
13. The adaptor protein PID1 regulates receptor-dependent endocytosis of postprandial triglyceride-rich lipoproteins.
Fischer AW; Albers K; Krott LM; Hoffzimmer B; Heine M; Schmale H; Scheja L; Gordts PLSM; Heeren J
Mol Metab; 2018 Oct; 16():88-99. PubMed ID: 30100244
[TBL] [Abstract][Full Text] [Related]
14. Quantitation of human apolipoprotein C-III and its subspecie by radioimmunoassay and analytical isoelectric focusing: abnormal plasma triglyceride-rich lipoprotein apolipoprotein C-III subspecie concentrations in hypertriglyceridemia.
Kashyap ML; Srivastava LS; Hynd BA; Gartside PS; Perisutti G
J Lipid Res; 1981 Jul; 22(5):800-10. PubMed ID: 7288286
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
Graham MJ; Lee RG; Bell TA; Fu W; Mullick AE; Alexander VJ; Singleton W; Viney N; Geary R; Su J; Baker BF; Burkey J; Crooke ST; Crooke RM
Circ Res; 2013 May; 112(11):1479-90. PubMed ID: 23542898
[TBL] [Abstract][Full Text] [Related]
16. Effects of severe caloric restriction on the degree of sialylation of apoprotein C-III in obese women.
Bosello O; Cominacini L; Zocca I; Garbin U; Ferrari F; Davoli A
Ann Nutr Metab; 1985; 29(1):33-9. PubMed ID: 3977292
[TBL] [Abstract][Full Text] [Related]
17. Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions.
Fredenrich A; Giroux LM; Tremblay M; Krimbou L; Davignon J; Cohn JS
J Lipid Res; 1997 Jul; 38(7):1421-32. PubMed ID: 9254067
[TBL] [Abstract][Full Text] [Related]
18. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome.
Julve J; Escolà-Gil JC; Rotllan N; Fiévet C; Vallez E; de la Torre C; Ribas V; Sloan JH; Blanco-Vaca F
Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):232-8. PubMed ID: 19910634
[TBL] [Abstract][Full Text] [Related]
19. ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
Chan DC; Watts GF
Curr Opin Lipidol; 2024 Jun; 35(3):101-109. PubMed ID: 38372218
[TBL] [Abstract][Full Text] [Related]
20. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
Schmitz J; Gouni-Berthold I
Curr Med Chem; 2018; 25(13):1567-1576. PubMed ID: 28595549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
